Thermogenesis, TotipotentRX say bone marrow stem cell milestone reached ThermoGenesis and TotipotentRX Corporation announced earlier that the TotiPotentRX cellular therapy clinical team in partnership with Fortis Healthcare achieved its 20th pediatric bone marrow transplant. ThermoGenesis are up 10% to $2.42 in early trading.
Cesca Therapeutics files IDE application for no-option critical limb ischemia Cesca Therapeutics has submitted an investigational device exemption application to the FDA for a pivotal multicenter study of the company's SurgWerks-CLI and VXP System for treating advanced stages of no-option lower limb critical limb ischemia. The IDE application is the result of two prior positive pilot and feasibility studies conducted in Italy and India, respectively, and collaborative pre-IDE feedback from the U.S. FDA. The primary endpoint is major amputation free survival at 12 months following enrollment.